Alemtuzumab

Drug Profile

Alemtuzumab

Alternative Names: Anti-CD52 monoclonal antibody; Campath; Campath-1H; LDP-03; Lemtrada; MabCampath; MabKampat; Remniq

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator University of Cambridge
  • Developer Bayer HealthCare Pharmaceuticals Inc.; Dana-Farber Cancer Institute; German CLL Study Group; Ohio State University Comprehensive Cancer Center; Sanofi Oncology; University of Cologne
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD52 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Multiple sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II T cell prolymphocytic leukaemia
  • Phase I Diffuse large B cell lymphoma; Graft-versus-host disease; T cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Apr 2017 Sanofi initiates enrolment in a phase III trial for Multiple sclerosis (In children, In adolescents) in Spain (EudraCT2016-003100-30)
  • 01 Oct 2016 Bayer completes a phase I trial in T-cell lymphoma and diffuse large B cell lymphoma (Combination therapy, First-line therapy) in USA (SC) (NCT00323323)
  • 14 Sep 2016 Pooled adverse events data from the phase III CARE-MS-I and CARE-MS-II trials in Multiple sclerosis presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top